<DOC>
	<DOCNO>NCT00292474</DOCNO>
	<brief_summary>The ultimate goal paclitaxel elute stent system ( TAXUS stent ) prevent restenosis blunt initial response stent implant injury sustain arrest response vascular heal take place . The purpose TAXUS IV-SR trial study safety efficacy TAXUS Stent control trial circumstance use treatment new coronary artery lesion ( heart blockages ) This clinical investigation evaluate safety effectiveness TAXUS Stent 1 ug/mm2 ( loaded drug/stent surface area ) paclitaxel incorporate slow rate-release formulation triblock copolymer carrier system treatment new coronary artery lesion .</brief_summary>
	<brief_title>TAXUS IV-SR : Treatment De Novo Coronary Disease Using Single Paclitaxel-Eluting Stent</brief_title>
	<detailed_description>This prospective randomized , double-blind , multicenter safety efficacy trial . Patients stratify presence absence medically treat diabetes mellitus vessel diameter ( &lt; 3.0 mm &gt; /=3.0 mm ) , randomize 1:1 receive either TAXUS Stent Control stent . Additional study stent permit optimize outcome . The study consider complete ( regard primary endpoint ) patient enrol complete 9 month follow-up . Enrollment 1172 patient plan ; 1326 treat randomize 73 center involve 76 site 8 July 2002 667 TAXUS group 659 Control group .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Patient &gt; = 18 year old 2 . Eligible percutaneous coronary intervention ( PCI ) 3 . Documented stable angina pectoris ( Canadian Cardiovascular Society Classification [ CCS ] 1 , 2 , 3 , 4 ) unstable angina pectoris document ischemia ( Braunwald Class IBC , IIBC , IIIBC ) , document silent ischemia 4 . Left ventricular ejection fraction ( LVEF ) &gt; = 25 % 5 . Acceptable candidate CABG 6 . Patient ( legal guardian ) understand study requirement treatment procedure provide write Informed Consent studyspecific test procedure perform 7 . Willing comply specify followup evaluation 1 . Target lesion locate within single native coronary vessel 2 . Target lesion randomize treatment study device may compose multiple lesion must completely coverable one ( 1 ) study stent 3 . Cumulative target lesion length &gt; = 10 mm &lt; = 28 mm ( visual estimate ) 4 . RVD &gt; = 2.5mm &lt; = 3.75 mm ( visual estimate ) 5 . Target lesion diameter stenosis &gt; = 50 % ( visual estimate ) 6 . Target lesion de novo ( i.e. , coronary lesion previously treat ) 7 . Target lesion locate within single native coronary vessel 8 . Target lesion randomize treatment study device may compose multiple lesion must completely coverable one ( 1 ) study stent 9 . Cumulative target lesion length &gt; = 10 mm &lt; = 28 mm ( visual estimate ) 10 . RVD &gt; = 2.5mm &lt; = 3.75 mm ( visual estimate ) 11 . Target lesion diameter stenosis &gt; = 50 % ( visual estimate ) 12 . Target lesion de novo ( i.e. , coronary lesion previously treat ) 1 . Known sensitivity paclitaxel 2 . Any previous plan treatment nonstudy antirestenotic drugcoated drugeluting coronary stent . ( Note : previous plan treatment heparin phosphorylcholine coat stent acceptable , long procedure nonstudy stent meet protocol define criterion stag procedure ) 3 . Previous plan treatment intravascular brachytherapy target vessel 4 . MI within 72 hour prior index procedure and/or CKMB &gt; 2x local laboratory 's upper limit normal ( refers measure value day index procedure ) 5 . Cerebrovascular Accident ( CVA ) within past 6 month 6 . Acute chronic renal dysfunction ( creatinine &gt; 2.0 mg/dl &gt; 150 Âµmol/L ) 7 . Contraindication ASA , clopidogrel ticlopidine 8 . Leukopenia ( leukocyte count &lt; 3.5 x 109/liter ) 9 . Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) 10 . Active peptic ulcer active gastrointestinal ( GI ) bleed 11 . Known allergy stainless steel 12 . Any prior true anaphylactic reaction contrast agent 13 . Known anaphylactoid nonanaphylactic allergic reaction contrast agent adequately premedicated prior index procedure 14 . Patient currently take colchicine 15 . Patient currently , treat paclitaxel within 12 month index procedure 16 . Female childbearing potential positive pregnancy test within 7 day index procedure , lactating , intend become pregnant study 17 . Life expectancy le 24 month due medical condition 18 . Comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study 19 . Currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>stent implant</keyword>
	<keyword>drug-coated stent</keyword>
</DOC>